HIV感染者结核病预防治疗的经济学与模型证据:系统综述与荟萃分析
该系统综述与荟萃分析检索了截至2020年12月31日的MEDLINE、Embase和Web of Science,纳入61项模型研究,其中31项报告成本与效果结局。所有研究均预测对HIV感染者提供结核病预防治疗可有效减少结核病,且具成本效果;但研究间参数与假设异质性大,比较困难。
要点
- 所有纳入模型研究均预测对HIV感染者提供TPT可有效减少结核病。
- 85%报告成本结局的研究中,TPT及后续成本低于每人1500美元(2020年美元)。
- 所有成本效果分析均认为TPT相比不提供TPT具潜在成本效果。
核心结论
- 所有模型研究均预测对HIV感染者提供结核病预防治疗可有效减少结核病且具成本效果,但研究异质性大。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE、Embase和Web of Science自建库至2020年12月31日,最终纳入61项模型研究,其中31项报告成本与效果结局。
主要发现
- 全部61项研究均预测TPT可有效减少结核病,无某方案显著优于其他方案。
- 85%报告成本结局的研究(n=36)中,TPT及后续成本低于每人1500美元(2020年美元),不受研究设置影响。
- 所有成本效果分析均认为TPT具潜在成本效果。
- 汇总增量净货币效益在LMICs为271美元(95%CI -81至622,p=0.12),在HICs为2568美元(-32115至37251,p=0.52)。
- 汇总活动性结核发病率降低百分比在LMICs为20%(13%至27%,p<0.001),在HICs为37%(-34%至100%,p=0.13)。
关键数值与推荐
- 多数研究考虑基于异烟肼(INH)的方案,疗程6至2个月(n=45)或长于12个月(n=11)。
- 国家收入分类、抗逆转录病毒治疗(ART)使用考虑及TPT方案使用显著影响成本效果。
临床怎么用
- 模型证据支持对HIV感染者提供TPT以预防结核病,且具潜在成本效果。
- 临床决策可参考TPT方案选择及ART使用等影响成本效果的关键因素。
局限性
- 纳入研究的输入参数与假设异质性大,限制效应估计的合并。
- 模型参数报告不一致,限制定量分析的样本量。
- 数据库偏倚偏向英文出版物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Human immunodeficiency virus (HIV) is the strongest known risk factor for tuberculosis (TB) through its impairment of T-cell immunity. Tuberculosis preventive treatment (TPT) is recommended for people living with HIV (PLHIV) by the World Health Organization, as it significantly reduces the risk of developing TB disease. We conducted a systematic review and meta-analysis of modeling studies to summarize projected costs, risks, benefits, and impacts of TPT use among PLHIV on TB-related outcomes. METHODS AND FINDINGS: We searched MEDLINE, Embase, and Web of Science from inception until December 31, 2020. Two reviewers independently screened titles, abstracts, and full texts; extracted data; and assessed quality. Extracted data were summarized using descriptive analysis. We performed quantile regression and random effects meta-analysis to describe trends in cost, effectiveness, and cost-effectiveness outcomes across studies and identified key determinants of these outcomes. Our search identified 6,615 titles; 61 full texts were included in the final review. Of the 61 included studies, 31 reported both cost and effectiveness outcomes. A total of 41 were set in low- and middle-income countries (LMICs), while 12 were set in high-income countries (HICs); 2 were set in both. Most studies considered isoniazid (INH)-based regimens 6 to 2 months long (n = 45), or longer than 12 months (n = 11). Model parameters and assumptions varied widely between studies. Despite this, all studies found that providing TPT to PLHIV was predicted to be effective at averting TB disease. No TPT regimen was substantially more effective at averting TB disease than any other. The cost of providing TPT and subsequent downstream costs (e.g. post-TPT health systems costs) were estimated to be less than $1,500 (2020 USD) per person in 85% of studies that reported cost outcomes (n = 36), regardless of study setting. All cost-effectiveness analyses concluded that providing TPT to PLHIV was potentially cost-effective compared to not providing TPT. In quantitative analyses, country income classification, consideration of antiretroviral therapy (ART) use, and TPT regimen use significantly impacted cost-effectiveness. Studies evaluating TPT in HICs suggested that TPT may be more effective at preventing TB disease than studies evaluating TPT in LMICs; pooled incremental net monetary benefit, given a willingness-to-pay threshold of country-level per capita gross domestic product (GDP), was $271 in LMICs (95% confidence interval [CI] -$81 to $622, p = 0.12) and was $2,568 in HICs (-$32,115 to $37,251, p = 0.52). Similarly, TPT appeared to be more effective at averting TB disease in HICs; pooled percent reduction in active TB incidence was 20% (13% to 27%, p < 0.001) in LMICs and 37% (-34% to 100%, p = 0.13) in HICs. Key limitations of this review included the heterogeneity of input parameters and assumptions from included studies, which limited pooling of effect estimates, inconsistent reporting of model parameters, which limited sample sizes of quantitative analyses, and database bias toward English publications. CONCLUSIONS: The body of literature related to modeling TPT among PLHIV is large and heterogeneous, making comparisons across studies difficult. Despite this variability, all studies in all settings concluded that providing TPT to PLHIV is potentially effective and cost-effective for preventing TB disease.
引用
- Uppal A, Rahman S, Campbell JR, et al. Economic and modeling evidence for tuberculosis preventive therapy among people living with HIV: A systematic review and meta-analysis. PLoS Med. 2021. PMID: 34520463. doi:10.1371/journal.pmed.1003712
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。